Results 281 to 290 of about 162,747 (308)

The bioavailability of oral and parenteral chlorimipramine (anafranil)

Progress in Neuro-Psychopharmacology, 1980
1. 1. Ten healthy volunteers were given 50 mg of chlorimipramine orally and intravenously with at least 3 weeks between administrations. 2. 2. Regular estimations of serum chlorimipramine and the metabolite desmethylchlorimipramine were undertaken during the 96 hrs following administration of the drug. 3. 3.
Evans, Larry E.J., Bett, J.H.Nick, Cox, John R., Dubois, Jean P., Van Hees, Thea   +4 more
openaire   +5 more sources

Bioavailability of cyclophosphamide from oral formulations

European Journal of Clinical Pharmacology, 1984
Cyclophosphamide (CP) is an alkylating cytostatic compound, which is activated to its cytotoxic form in the liver [1]. Since the therapeutic range of CP in the treatment of human tumours, is small like other cytostatics, a constant high bioavailability is essential for its oral administration.
T, Wagner, K, Fenneberg
openaire   +2 more sources

Bioavailability of valsartan oral dosage forms

Clinical Pharmacology in Drug Development, 2013
AbstractThe oral bioavailability of valsartan from extemporaneous suspension and solution formulations were evaluated relative to tablet formulation in two separate open‐label, randomized crossover studies in healthy adults. In both studies, the plasma concentrations of valsartan after oral administration were analyzed using validated liquid ...
Gangadhar, Sunkara, Girish, Bende, Anisha E, Mendonza, Susan, Solar-Yohay, Shibadas, Biswal, Srikanth, Neelakantham, Robert, Wagner, Jimmy, Flarakos, Yiming, Zhang, Venkateswar, Jarugula   +9 more
openaire   +2 more sources

Risperidone: Effects of Formulations on Oral Bioavailability

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997
The bioavailability of risperidone was evaluated in an open‐label, randomized, two‐way, crossover study comparing a 1‐mg tablet with a 1‐mg/ml oral solution. Both formulations were administered as a single 1‐mg dose with a 10‐day washout period between treatments. Of 26 healthy men who entered the study, 23 completed both treatment periods.
R, Gutierrez, P I, Lee, M L, Huang, R, Woestenborghs   +3 more
openaire   +2 more sources

Pharmacokinetics and oral bioavailability of carbimide in man

Biopharmaceutics & Drug Disposition, 1991
AbstractA pharmacokinetic study of carbimide, an inhibitor of aldehyde dehydrogenase, used as an adjuvant in the aversive therapy of chronic alcoholism, has been carried out in male human volunteers for intravenous and oral administration.
R, Obach, J, Torrent, H, Colom, J, Pruñonosa, C, Peraire, J, Domenech   +5 more
openaire   +2 more sources

Lipid nanoparticles for enhancing oral bioavailability

Nanoscale
In recent studies, lipid nanoparticles have attracted attention as drug delivery systems owing to their preeminent potential in achieving the desired bioavailability of biopharmaceutics (BCS) class II and class IV drugs.
Anushareddy Gangavarapu, Lillian V. Tapia-Lopez, Barnali Sarkar, Jaqueline Pena-Zacarias, Abu Zayed Md Badruddoza, Md Nurunnabi   +5 more
openaire   +2 more sources

Bioavailability of Oral Physostigmine

New England Journal of Medicine, 1985
R, Whelpton, P, Hurst
openaire   +2 more sources

Review of the bioavailability and pharmacokinetics of oral norfloxacin

The American Journal of Medicine, 1987
The pharmacokinetic profile of norfloxacin, an oral fluoroquinolone, is more complex than that of many antibacterial agents. Following administration of a 400-mg dose, peak serum concentrations of 1.5 to 2.0 micrograms/ml are achieved within one to two hours.
openaire   +2 more sources

Measuring oral bioavailability of tacrolimus

Pediatric Transplantation, 2014
Gideon, Koren, Michael, Rieder
openaire   +2 more sources

<p>The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs</p>

International Journal of Nanomedicine, 2020
Chao Pi, Yi Hou, Ling Zhao
exaly